MOR News
Archived Headlines
- MorphoSys launches $200 million US IPO in largest biotech listing in a decade 04/09/18
- US IPO Week Ahead: Subscription unicorn Zuora kicks off the 2Q IPO market 04/06/18
- US IPO Week Ahead: Spotify's long-awaited direct listing 03/29/18
- German cancer biotech MorphoSys files for a $150 million US IPO 03/22/18
US IPO Weekly Recap: Pivotal Software gains 5% as 5 IPOs price and 3 delay
• 8 IPOs had planned to raising $2.6 billion, but instead 5 IPOs raised $1.4 billion • Despite tech sector's strength, top-performer Pivotal Software gained just 5%; week averaged 2% •...read more
How do listed companies perform with a US IPO?
US equity markets are an attractive source of capital and liquidity, even for companies that are already listed on foreign exchanges or the OTC markets. Frankfurt-listed MorphoSys (MOR) began trading on Thursday, and four more traded...read more
Cancer biotech MorphoSys prices $208 million US offering at $25.04
MorphoSys, which is licensing antibodies to pharmas and developing its own novel therapies, raised $208 million in its US initial public offering. Listed on the Franfurt Stock Exchange, MorphoSys offered 8.3 million ADSs at $25.04, a 6.5% discount to the as...read more
US IPO Week Ahead: A pivotal week with 8 IPOs
Eight deals are on the calendar for the week ahead looking to raise a combined $2.6 billion. Headlining the week is DellEMC spin-off Pivotal Software, which provides a platform for enterprises to manage cloud-based apps. The company is...read more